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Abstract 
Although it is important to understand the molecular mechanisms underpinning muscle 
wasting with aging, it is ultimately the failure of cell function that leads to all aging 
phenomena. Part of the cause of cellular dysfunction in old age is thought to be chronic, 
low grade, systemic inflammation in the face of reduced anabolic drives. Skeletal muscle 
and its resident stem cells provide good models of cellular and tissue failure with age.  Easy 
access to muscle-derived stem cells provides a tool with which to assess local vs. 
environmental triggers of age-related cellular dysfunction. The aim of this study was to 
develop relevant models of age-related muscle wasting. The hypothesis was that older 
muscle cells would be more prone to catabolic and less prone to anabolic adaptation vs. 
younger muscle cells. Objectives were to compare and contrast younger and older skeletal 
muscle cell adaptation to anabolic (IGF-I) and catabolic (IL-6 and TNF-α) stimuli. 
In the murine model, and in line with expectations, IGF-I (100 ng/ml) resulted in improved 
fusion in younger, but reduced fusion in older myoblasts. By contrast, and unexpectedly, in 
human myoblasts the opposite occurred, where IGF-I (100 ng/ml) resulted in reduced 
fusion in younger, but increased fusion in older myoblasts. Where improved fusion was 
evident (regardless of model or age) with IGF-I administration, this was associated with 
enhanced basal fusion potential, which should therefore be considered when choosing 
models of study. It is currently not known what drives altered basal fusion capability and 
the subsequent enhanced response to IGF-I. Therefore, the two models together provide 
an opportunity to further investigate this finding.  
When assessing the impact of catabolic cytokines on myoblast fusion, both models 
displayed increased negative adaptation in older vs. younger myoblasts. However, and 
interestingly, older murine myoblasts were more responsive to TNF-α and older human 
myoblasts to IL-6 administration. The impaired differentiation in response to the cytokines 
may underlie the muscle wasting evident in older age, and again provides a good model of 
study. 
In conclusion, evidence is provided here of the development of muscle models for 
investigating muscle aging in vitro.  Early data suggest that care should be taken when 
choosing the model and this should be driven by the final question being addressed e.g., 
the model for studying hypertrophy may not be the best model for studying atrophy.
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1.1  Literature review 
1.1.1. Skeletal Muscle  
The human body is largely comprised of skeletal muscle and accounts for 50% of the total 
body mass in young age. This reduces about 25% of total bodyweight by 75-80 years of age 
(Kalyani et al., 2014). It is the largest protein reservoir and is a source of amino acids utilised 
for energy production by a variety of organs during catabolic periods, such as starvation 
depletion, burn injury, heart failure, cancer, sepsis, and AIDS (Figure.1.1). In order to 
produce glucose, the liver uses amino acids from muscle protein breakdown (Bonaldo & 
Sandri, 2013; Wolfe, 2006). In addition,  with aging, both muscle mass and regenerative 
capacity are gradually lost (Manini et al., 2013). 
When protein degradation exceeds protein synthesis, reduced muscle bulk occurs leading 
to a decrease of the cross-sectional area of myofibres and muscle strength (Schiaffino & 
Dyar, 2013; Kalyani et al., 2014). Moreover, extreme protein degradation in skeletal muscle 
has severe consequences on the human body including the possibility of death (Bonaldo & 
Sandri, 2013; Argilés et al.,2016). Furthermore, the effectiveness of various therapeutic 
treatments can be impaired by the disproportionate loss of muscle mass (Wüst & Degens, 
2007; English & Douglas Paddon-Jones, 2010; Kalyani et al., 2014). The prevention of 
metabolic disorders, facilitation of healthy age progression and the provision of energy to 
vital organs during stressed conditions largely depends on the maintenance of healthy 
muscles. In adults, muscle mass and performance adjust to diverse pathophysiological 
conditions through the activation of pathways that control protein turnover (Bonaldo & 
Sandri, 2013). Endurance, strength, and physical performance are largely contingent upon 
skeletal muscle mass (Costa et al., 2012). 
1.1.2. Skeletal muscle atrophy 
During atrophy, there is a major reduction in protein content, fibre diameter, force 
production, and fatigue resistance (Dodson et al., 2011; Williamson et al., 2003). It is a 
typical response to such conditions as starvation, aging (sarcopenia) and inactivity. 
However, it may also present as a symptom of other chronic diseases such as cancer 
(cachexia), diabetes, sepsis, AIDS, renal and heart failure (Fanzani et al., 2012). These all 
contribute to the  morbidity and early mortality of the patient (Vinciguerra et al., 2010). 
3 
Many triggers of significant decreases in muscle, body weight and fat are due to increased 
protein catabolism driven by tumour-derived factors, anorexia and endocrine changes 
(Ebadi & Mazurak, 2014). Important endocrine changes include elevated TNF-α, which is 
known to induce skeletal muscle catabolism via, among others, the ubiquitin-proteasome 
system (UPS) (Sandri, 2013; Bonaldo & Sandri, 2013). Increased catabolic signalling, 
oxidative stress, reduced anabolic signalling, and reduced protein synthesis are additional 
processes involved in the pathogenesis of muscle atrophy (McCarthy & Esser, 2010; 
Bonaldo & Sandri, 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Muscle atrophy. 
Muscle atrophy can result as a consequence of many different physiological and pathological conditions. (Fanzani et 
al., 2012). 
 
1.1.3. Sarcopenia 
Age-related muscle loss (termed sarcopenia) is the loss of skeletal muscle mass and 
function associated with aging. It is a serious geriatric clinical disorder affecting more than 
half of the population over 80 years ( Cruz-Jentoft et al., 2010; Loeser, 2010). Humans over 
the age of 50 generally lose 1-2% of muscle mass per year (Hughes et al., 2002). This has a 
direct effect on muscle strength, muscle functionality, and metabolic performance and 
ultimately morbidity and mortality (Bonaldo & Sandri, 2012; Muscaritoli et al., 2013). 
Sarcopenia is multifactorial and includes factors such as chronic inflammatory diseases, 
disuse and malnutrition (Biolo et al., 2014). 
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The decline in muscle mass with aging is accompanied by a decrease in the number and 
size of muscle fibres (Michel et al., 2004; Evans, 2010) . It has been established that by the 
eighth decade a 50% decline in the total fibre number is present when compared with 
muscle tissue in young subjects and that the cross- sectional area of type II fibres is nearly 
35% smaller in muscles from older individuals when compared with young individuals 
(Mitchell et al., 2012; Nilwik et al., 2013). A growing body of literature generally agrees that 
type II fibre atrophy occurs with age whereas type I fibre size remains unchanged  
 
(Deschenes, 2004; Lee et al., 2006). Researchers have demonstrated that any differences 
detected could either be attributed to age or simply inactivity (Klitgaard et al., 1990). 
Studies have been conducted that show that elderly strength-trained subjects have cross-
sectional areas larger than that of sedentary subjects and similar to those of young adult 
control subjects, proposing that age-related changes in skeletal muscle function may be 
responded to by long-term strength-training in elderly men. 
Increased levels of circulating cytokines and catabolic hormones are associated with muscle 
atrophy (Figure.1.1) (Costamagna et al., 2015b), however, the current lack of available 
effective therapies to slow or reverse muscle loss is hampered by limitations in the 
understanding of the pathogenesis of muscle atrophy (Bodine, 2013). 
1.1.4. The role of satellite cells in adult muscle 
The impaired function of skeletal muscle stem cells or satellite cells may be a factor 
underlying muscle atrophy (Mann et al., 2011; Snijders et al., 2015). Satellite cells are 
mono-nucleated myogenic precursor cells (myoblasts) located between the basal lamina 
and the plasma membrane of muscle fibres and are primary factors in muscle regeneration 
(Yablonka-Reuveni, 2011; Yin et al., 2013). While they are generally in a quiescent 
undifferentiated state, when activated in reaction to muscle damage, they are able to 
proliferate, migrate to the site of injury and fuse with existing fibres for regeneration and 
hypertrophy (Mauro, 1961; Yin et al., 2013; Dumont et al., 2015). 
  
5 
1.1.5. Impairment of satellite cell function in repair and hypertrophy 
The regenerative capacity of postnatal skeletal muscle is deemed largely dependent on 
satellite cells (Figure.1.2). 
 
 
 
 
 
 
 
 
Figure 1.2. Role of satellite cells in muscle regeneration (Hawke and Garry, 2001). 
 
During embryogenesis, skeletal muscle precursor cells (MPCs) originate in somites and 
undergo a multi-process of lineage commitment, migration, proliferation and 
differentiation (Kawiak et al., 2006; Bentzinger et al., 2012) (Figure.1.3). 
 
Figure 1.3. Satellite cell activation and maturation. Adapted from (Zammit et al., 2006).
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1.1.6. Age-dependent decline in stem cell functionality of satellite cells 
The decrease in the stem cell functionality of satellite cells with age, is possibly attributed 
to intrinsic molecular variations in aged muscle stem cells or extrinsic changes due to the 
aging of the local microenvironment (e.g. myofibres and the extracellular matrix) or the 
systemic environment (Dumont et al., 2015). Several groups have reported age-associated 
reductions in the number of satellite cells and hypothesised that this loss of satellite cells 
ultimately contributes to the aged-related muscle atrophy (Shadrach & Wagers, 2011; Oh, 
2015; Snijders et al., 2015). 
The murine C2 and C2C12 skeletal myoblasts provide established models to investigate 
some of the processes of muscle cell adaptation during aging.  Historically, research within 
our laboratory has been conducted using C2 cells that were originally established following 
C3H leg muscle crush-injury (Yaffe & Saxel, 1977).The daughter C2C12 cells are a subclone 
of the parental C2 line (Chiu & Blau, 1985) and were generated for their differentiation 
potential. The former provides a model for younger muscle cells with sustained 
hypertrophy potential, while the latter provides a model of atrophying older muscle 
(Sharples et al., 2010). Use of the two lines in parallel, provide an opportunity to begin to 
investigate cellular adaptation with age and inflammation. 
1.1.7. Skeletal muscle hypertrophy 
Skeletal muscle hypertrophy is defined by an increase in the muscle mass and in the cross-
sectional area of the fibres (Paul & Rosenthal, 2002). Generally, muscle hypertrophy is 
related to strength training or conditions associated with increased protein synthesis 
(Schoenfeld, 2010; Kalyani et al., 2014). 
The induction of hypertrophy is associated with incorporation of new myonuclei (provided 
by satellite cells) into the fibres which enable increased protein synthesis and a constant 
myonuclear domain (Shenkman et al., 2010). During the embryonic and post-embryonic 
periods, the satellite cells play an important role in muscle growth. It is accepted that 
satellite cells have an important role during muscle hypertrophy, also in adults, given 
appropriate stimuli. Some controversy does, however, exist, as McCarthy et al (2011), using 
a genetic mouse model to conditionally ablate satellite cells, reported that while satellite 
cells were not required for muscle hypertrophy, they were essential for the formation of  
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new fibres and for muscle regeneration (McCarthy et al., 2011). Therefore, although the 
precise role of the satellite cell in adult hypertrophy is debatable, there is a clear need for 
these cells in regeneration.  
1.1.8 Insulin-Like Growth Factor (IGF-I) 
As mature muscle fibres are post mitotic, in order to enable regeneration, they are 
dependent on the recruitment of satellite cells, which involves both cytokines and growth 
factors. An important growth factor in skeletal muscle biology is Insulin like Growth Factor 
I (IGF-I) (Shadrach & Wagers, 2011; Philippou et al., 2007). Indeed, IGF-I has been shown to 
enhance protein synthesis, to increase the size of myotubes, ( Velloso, 2008), to suppress 
protein degradation (Wang & Mitch, 2014), and to increase the number of satellite cells 
(Velloso, 2008; Zhang et al., 2010). Indeed, increased endogenous expression of the IGFs in 
murine myoblast cell lines (e.g. C2 and C2C12) is associated with spontaneous fusion upon 
transfer to low serum differentiation medium (Florini et al., 1991; Stewart & Rotwein, 
1996). 
The IGF system includes: two IGFs (IGF-I and IGF-II), the type I and type II IGF cell surface 
receptors, six specific high-affinity binding proteins (IGFBPs-1 to -6), IGFBP proteases, and 
other IGFBP-interacting molecules (Clemmons, 1997).  All play a role in embryonic, foetal 
and adult development and perform a wide array of biological functions (Sharples et al., 
2015).  Reduced levels of the IGF-I gene transcripts in skeletal muscle (by up to 45% in older 
vs. younger males (Léger et al., 2008) during  aging (Benbassat et al., 1997; C. Velloso, 
2008), may be associated with a reduction in Growth Hormone (GH) levels and sensitivity 
(Figure.1.4). 
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Figure 1.4. GH deficiency and Aging (Bartke, 2005). 
 
 
The binding of IGF-I to its receptor stimulates several downstream signalling events 
including the activation of the MAP kinase (Erk 1/2) and PI 3-kinase pathways as detailed 
in Figure.1.5 (Singleton & Feldman, 2001). 
 
 
Figure 1.5. The role of IGF in stimulating proliferation and differentiation (Singleton and Feldman et al 2001).  
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In human studies, muscle from older men has higher levels of MAPK proteins compared to 
those of younger men (Williamson et al., 2003). The importance of the PI3K/Akt pathway 
has been illustrated in C2C12 myoblasts using inhibitors of PI3K, which attenuated the 
process of hypertrophy (Rommel et al., 1999; Glass, 2005; Sharples & Stewart, 2011). 
Substantiation has been provided in animal models through the knock down of Akt1, which 
resulted in smaller and lighter animals compared with wild type control (Florian Bentzinger 
et al., 2013). Furthermore, work by (Lai et al., 2004) demonstrated that activation of Akt 
was sufficient to cause a 73% increase in quadriceps muscle size in mice. Thus the age-
related decrease in IGF-I may underlie the decreased proliferation and differentiation of 
myoblasts in older age (Arthur & Cooley, 2012). Furthermore, IGF-I has been shown to 
decrease fibrosis and control the inflammatory response following injury, by down-
regulating pro-inflammatory cytokines (Speca et al., 2012). 
1.1.9 Tumour Necrosis Factor Alpha (TNF-α) 
TNF-α, a pleiotropic pro-inflammatory cytokine, which along with other cytokines is 
secreted by a number of cells such as: myoblasts, neutrophils, macrophages, fibroblasts, 
vascular smooth muscle cells and vascular endothelium (Li & Reid, 2000; Otis et al., 2014)  
These cytokines are usually produced in response to damage or infection of tissue and form 
part of the normal inflammatory response (Zhang & Zheng, 2007) . However, in diseases 
such as advanced HIV, cancer, chronic infections (Deeks et al., 2013;  Ali et al., 2013) and 
sarcopenia (Sakuma & Yamaguchi, 2012), prolonged and increased expression of these 
cytokines are believed to underpin catabolism and therefore wasting of skeletal muscle 
(Grounds, 1998; Reid & Li, 2001; Tajrishi et al., 2014). TNF-α blocks myogenic differentiation 
(Li et al., 1998; Langen et al., 2001; Li et al., 2014)  and causes extensive cell death in C2 
cells (Stewart et al., 2004) via a plethora of signalling pathways (Figure.1.6). Cell culture 
studies have additionally demonstrated that prolonged exposure of differentiated 
myotubes to clinically relevant levels of TNF-α (1-6 ng/ml) stimulates muscle protein 
degradation (Li et al., 1998). 
 
 
 
 
10 
 
 
Figure 1.6. TNF-α signalling pathway. Taken from (Mocellin et al., 2005). 
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1.1.10 Interleukin (IL-6) 
IL-6, a pleiotropic cytokine, is produced by a number of cells including: myoblasts, 
myofibres, adipocytes, macrophages, neutrophils, endothelial cells and osteoblasts (Yin et 
al., 2013; Muñoz‐Cánoves et al., 2013). IL-6 exerts its effects following cell surface receptor 
binding and activation of a host of signaling pathways, illustrated in Figure.1.7). 
 
 
 Figure 1.7. IL-6 signalling pathway. Taken from (Ni et al., 2004). 
 
IL-6 mRNA knockdown decreases muscle-specific gene expression in cultured C2C12 
myoblasts (Baeza-Raja & Muñoz-Cánoves, 2004; Serrano et al., 2008) , suggesting an anti-
myogenic role for this cytokine (Muñoz‐Cánoves et al., 2013). IL-6 infusion or over-
expression in murine models induces muscle atrophy (Muñoz‐Cánoves et al., 2013; B. K. 
Pedersen & Steensberg, 2004). Despite these data, IL-6 is also reported to have beneficial 
effects in skeletal muscle, being linked with hypertrophy and myogenesis (Serrano et al., 
2008; Muñoz‐Cánoves et al., 2013). Supportive evidence derived from IL-6 knock-out 
models revealed a blunted hypertrophy response compared with wild-type controls. The 
contrasting effects of IL-6 on muscle remain to be explained, but one possibility is that 
endogenous levels produced during non-inflammatory situations are beneficial, whereas 
when IL-6 is overproduced in scenarios where inflammation or other pathological 
processes are occurring it is detrimental. 
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1.1.11 Protein synthesis/degradation imbalance 
An imbalance between protein synthesis and protein degradation, resulting in the increase 
of damaged proteins, is also associated with aging skeletal muscle and sarcopenia ( Kalyani 
et al., 2014). The rate of protein synthesis in aged muscle is diminished. There are 
numerous causes of decreased protein synthesis in aged skeletal muscle, such as 
underproduction of circulating and tissue-associated GH and IGF-I (Arthur & Cooley, 2012). 
Low levels of IGF-I in aged muscle are related to the high expression of muscle growth 
inhibitors including the pro-inflammatory cytokines TNF-α and IL-6. In skeletal muscle of 
aged (70 y) subjects, there is a 45% decrease in growth hormone receptor protein (GHRS) 
and IGF-I mRNA, along with a 2.8 fold increase in TNF-α  mRNA relative to young (20 y) 
subjects (Arthur & Cooley, 2012). Aged women with lower IGF-I levels and greater IL-6 
relative to younger women, demonstrate aspects of disability and early mortality (Arthur 
& Cooley, 2012). 
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1.2. Summary 
Although it is important to understand the molecular mechanisms underpinning muscle 
wasting with aging, it is ultimately the failure of cell function that leads to all aging 
phenomena. Part of the cause of cellular dysfunction in old age is thought to be chronic, 
low grade, systemic inflammation in the face of reduced anabolic drives. Skeletal muscle 
and its resident stem cells provide good models of cellular and tissue failure with age. Easy 
access to muscle-derived stem cells provides a tool with which to assess local vs. 
environmental triggers of age-related cellular dysfunction.  
At the outset of this programme of research, it was hypothesised that murine and human 
myoblasts could be utilised interchangeably as models of muscle aging and atrophy. To 
investigate this concept, in chapter 3, models of older (C2) and younger (C2C12) murine 
myoblast lines are used. The impact of anabolic (IGF-I) and catabolic (IL-6 and TNF-α) stimuli 
on their differentiation capacity are investigated.  Chapter 4 extends these studies through 
the use of primary myoblasts derived from old and young human muscle. These cells are 
similarly exposed to anabolic (IGF-I) and catabolic (IL-6 and TNF-α) stimuli, with 
differentiation as the output measure. The objectives were to investigate the basal fusion 
potential of older and younger myoblasts and to examine the subsequent impact of growth 
factor/cytokine administration on myoblasts differentiation. Finally, in chapter 5, the 
potential of these cells as future models of aging muscle are compared and contrasted. 
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Chapter 2 
Materials and Methods 
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2.1. Materials  
2.1.1. Chemicals, solvents and reagents  
Details regarding plastic ware and chemicals and solvents (analytical (AnalaR) or molecular 
biology/tissue culture grade) are presented in Tables.2.1 and 2.2. 
Table 2.1. List of Plastic ware 
Name Company 
Plastic ware Greiner Bio-one, (Kremsmunster, Austria) 
Cryogenic vials Nalgene, (NY, USA), 
Cell scrapers Nalgene, (NY, USA), 
Syringes Terumo, (Leuven, Belgium) 
500-ml bottle top filters Corning, (NY, U.S.A) 
0.22 and 0.2 µm syringe filters   Corning, (NY, U.S.A) 
96-well clear UV plates  BD Biosciences (San Jose, USA) 
96-well plates for protein assays Thermo Fisher Scientific ( Roskilde, Denmark) 
Flowcytometry tubes BD Biosciences (San Jose, USA) 
Pipette tips for tissue culture Fisher Scientific UK (Loughborough, UK) 
Neubauer haemocytometer (Sondheim, Germany) 
Isopropyl alcohol (IPA) freezing chamber Nalgene (NY, USA) 
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Table 2.2. List of tissue culture reagents 
Name Company 
Heat-inactivated (hi) foetal bovine serum (FBS) (Life Technologies,UK ) 
Heat-inactivated newborn calf serum (hiNCS) Gibco (Paisley, Scotland) 
Heat-inactivated horse serum (HS) TCS Biosciences (Corby, England) 
Penicillin/streptomycin and trypsin Bio Whittaker (Wokingham, England) 
L-glutamine BDH (Poole, England) 
Gelatin type A from porcine skin Sigma (St. Louis, USA) 
Glass ware Oxoid (Basingstoke,  England) 
Phosphate-buffered saline (PBS) Oxoid (Basingstoke, England) 
Trypsin or TryPLE Express (Life Technologies, UK) 
Medium 199 (Invitrogen, UK) 
Gentamycin (Invitrogen.UK) 
Recombinant human epidermal (Sigma, UK) 
growth (Hu EGF) and dexamethasone (Life Technologies, UK) 
Recombinant human insulin (Life Technologies, UK) 
Epidermal growth factor (EGF) (Life Technologies, UK) 
Recombinant human fibroblast (Life Technologies, UK) 
growth factor-basic (FGFb) (Life Technologies, UK) 
Recombinant human fibroblast growth-basic (FGFB) (Life Technologies, UK) 
Bovine fetuin (Life Technologies, UK) 
Dimethyl sulphoxide ( DMSO) (BDH, UK) 
Trypan blue stain (Bio Whittaker, UK) 
Texas Red_-X Phalloidin (Sigma Aldrich, UK) 
Anti-Myosin Heavy Chain (MyHC) (Bioscience, UK) 
DAPI (4',6-diamidino-2-phenylindole) (IHC World, USA) 
 
2.1.2. Biochemical assays 
Protein and creatine kinase (CK) activity analyses were performed using a Bio-Tek ELISA 
plate reader and analysed with Bio-Tek KC Junior Microplate. Data Analysis Software, 
(Winooski, USA). Reagents for protein assays were purchased from Pierce (Division of 
Thermo Fisher Scientific, Roskilde, Denmark) and CK reagents were from (Catachem, USA). 
2.1.3. Cell Origin 
Mouse C2 skeletal myoblasts were originally from the American Tissue Culture Collection 
(ATCC) Rockville, MD, USA. They are derived from crush-injured murine C3H leg muscle 
(Yaffe & Saxel, 1977). Human cells were kindly donated by the laboratories of Prof. G. 
Butler-Browne. The compositions of cell culture media are presented in table. 2.3. 
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2.1.4. Cell culture medium 
Table 2.3. Composition of cell culture media 
Types of 
medium 
Mouse cells Human cells 
Growth medium 
(GM) 
GM constituted: 400 ml 
DMEM with foetal bovine 
serum (hiFBS; 10%), hi 
newborn calf serum 
(hiNCS; 10%), L–
glutamine (2 mM), and 
penicillin-streptomycin. 
(1%). GM was stored at 
4°C and used within 2 
months. 
GM constituted: 320 ml DMEM and 80 ml 
Medium199. Final concentrations of 
supplements were as follows: hiFBS (20%), 
gentamycin (50 µg/ml), dexamethasone (0.2 
µg/ml) recombinant human epidermal growth 
(Hu EGF; 5 ng/ml), bovine fetuin (25 µg/ml) 
recombinant human fibroblast growth-basic 
(rhFGF; 0.5 ng/ml) and recombinant human 
insulin (5 µg/ml). GM was stored at 4°C and 
used within 2 months. 
Differentiation 
medium (DM) 
DM constituted: DMEM, 
hiHS (2%), Pen-strep 
(penicillin/Streptomycin) 
(1%), L-glutamine (2 
mM). DM was stored at 
4°C and used within 2 
months. 
DM constituted DMEM, insulin (10 μg/ ml), 
gentamycin (50 μg/ ml). DM was stored at 4°C 
and used within 2 months. 
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2.1.5. Cell Handling 
All cell culture was performed in a microbiological safety cabinet (Labcaire SC-R 
Recirculating Class II, UK). All cells were incubated in a Triple Red Laboratory Technology 
NuaireTM DH AutoFlow CO2 Air Jacketed Incubator (Buckinghamshire, UK). A Leica 
DMI6000B microscope (Wetzlar, Germany) was used to capture photomicrographs.  
2.2. Methods 
2.2.1. Culture of skeletal myoblasts 
The C2C12 cells are a subclone of the C2 cell line (Chiu & Blau, 1985). Human C83 cells are 
from an older donor and C25 from a younger donor. Murine and human myoblasts 
maintain a fibroblast-like phenotype in GM, but rapidly withdraw from the cell cycle and 
undergo myogenic differentiation upon serum reduction (transfer to DM). Growth of cell 
cultures to confluency and routine maintenance were carried out in a class II laminar flow 
hood using aseptic techniques. Cells were rapidly thawed and seeded onto 0.2% gelatine-
coated 75-cm2 flasks supplemented with GM. Cells were maintained in humidified 
incubators at 5% CO2 and 37°C . Media were replaced every 24-48 hours. Upon attaining 
90-100% confluency cells, were washed in phosphate-buffered saline (PBS), trypsinised, 
counted and sub-cultured for expansion or experimentation. Cell viability was determined 
using trypan blue counting and a Neubauer haemocytometer (see below and Figure.2.1). 
Cells not used for experiments or subculture were frozen at 1×106 cells/ml in GM plus 
dimethyl sulphoxide (DMSO; 10%). The cells were transferred to an isopropyl alcohol 
freezing chamber (Nalgene, NY, USA) and placed at -80°C to freeze the samples at a rate of 
1°C/min. Following 24h, the cells were transferred and stored in a Statebourne cryogenics 
liquid nitrogen storage tank.
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2.2.2. Differentiation of myoblasts 
At confluence and following two washes with PBS, myoblasts were induced to differentiate 
by replacing GM with DM. After 48 hours (murine myoblasts) and (human cells), myotube 
formation became evident and progressed over the following 24-48 hours. Morphological, 
biochemical, flow cytometric and protein analyses were performed over a relevant time 
course as detailed below. 
2.2.3. Cell counting by trypan blue exclusion 
Cell counting was performed using a Neubauer haemocytometer (Figure.2.1). Data derived 
from this enabled the cell number per ml of suspension to be calculated. The proportion of 
dead cells was determined using the cell viability stain, trypan blue, which penetrates 
membranes of non-viable cells only. A mixture of cells: trypan blue (1:1) were counted in 
four grids (Figure.2.2) with each individual counting area of the haemocytometer 
representing a total volume of 0.1 mm3. The cell number per ml was calculated using the 
following calculation:  
 
Equation 2.1. Calculation of viable and dead cell number following haemocytometer counting 
Total cell number is calculated by multiplying the cells per ml with the total volume of the cell suspension from which 
the cells sample was removed.  
 
  
Cells per ml = Average cell count in 4 grids /4 × dilution factor × 
1×104 
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Figure 2.1. Neubauer haemocytometer (Figure taken from www.sigmaaldrich.com). 
 
 
 
Figure.2.2. Haemocytometer counting grid (Figure taken from (www.sigmaaldrich.com). 
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2.2.4. Reconstitution of cytokines 
Recombinant human TNF-α (Life Technologies, UK) was reconstituted in 100 µl sterile 
filtered water to produce a stock solution of 100 µg/ml. Recombinant human IGF-I (Life 
Technologies, UK) was reconstituted in 200 μl to produce a stock solution of 100 µg/ml.  
Recombinant human IL-6 (Life Technologies, UK) was reconstituted in 50 μl of acetic acid 
to produce a stock of 100 µg/ml. All stocks were stored at -20°C until required. 
2.2.4.1.   Culture with human recombinant cytokines 
For experimentation, myoblasts were plated in duplicate in gelatin-coated plates at 
densities of: 60,000 cells per well (6-well plate) for mouse myoblasts and 100.000 calls per 
well (12-well plate) for human cells. Following overnight incubation, GM was aspirated and 
replaced with DM in the absence or presence of TNF-α (10 or 20 ng/ml), IL-6 (10 or 20 
ng/ml) or IGF-I (30 or 100 ng/ml). Time courses of harvesting were performed as 
appropriate. 
2.2.5. Cell lysis for creatine kinase (CK) and total protein assays 
Following incubation for relevant times, cells were washed twice in PBS and lysed in 
Tris/MES Triton (50 mM Tris-MES, pH 7.8, 1% Triton X-100). Cells were lysed at room 
temperature for 10 minutes prior to storage at -20°C. Protein and CK assays were all 
completed within 2 weeks of the sample being obtained. 
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2.2.5.1.   Creatine kinase assay 
Creatine kinase (CK) activity can be used as a biochemical marker of the progression of in 
vitro muscle cell differentiation. In the creatine kinase assay, endogenously derived CK 
catalyses the reaction between creatine phosphate and adenosine diphosphate (ADP), 
forming creatine and adenosine triphosphate (ATP). Within this assay, the ATP formed is 
utilised to phosphorylate glucose, producing glucose-6-phosphate (G-6-P) in the presence 
of hexokinase (HK). Subsequently, G-6-P is oxidised to 6-phosphogluconate (6-PG) in the 
presence of nicotinamide adenine dinucleotide (NAD). This reaction is catalysed by glucose-
6-phosphate dehydrogenase (G-6-PDH). During the oxidation, an equimolar amount of 
NAD is reduced to NADH increasing the absorbance at 340nM. The rate of change of 
absorbance is directly proportional to endogenous CK activity. 
 
Creatine phosphate + ADP   Creatine + ATP 
ATP + Glucose     ADP + G-6-P 
G-6-P + NAD   6-PG + NADH  Increased absorbance at 340nm 
Equation 2.2. Enzyme reactions involved in the creatine kinase (CK) assay (Smith et al., 1985) 
 
  
CK 
HK 
G-6-PDH 
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2.2.5.2.   Creatine kinase assay procedure 
Cells were differentiated for the relevant time periods prior to washing and harvesting as 
detailed above. The CK assay was performed at room temperature as follows: 4 µl of 
sample was added to 200 µl CK reagent in duplicate in a 96-well UV transparent flat-bottom 
plate. The contents were mixed and incubated for 3 minutes prior to serial reading (every 
minute for up to 20 minutes) at 340 nm using an ELx800 microplate reader (Biotek, USA). 
Initial and final readings were used to calculate the change in absorbance per minute 
(ΔA/min). CK activity (U/l) was calculated using the following equation: 
 
CK activity was then determined using the following calculation:  
 
Where: 
ΔA/min = Change in absorbance per minute at 340 nM 
TV  = Total volume (ml) 
SV  =  Sample volume (ml) 
6.22  = Millimolar absorptivity of NADH at 340 nm 
1000  = Conversion of Units per ml to Units per litre.  
Therefore using 10 μl of sample and 200 μl of reagent the following equation applies:  
 
Equation 2.3. Calculation of creatine kinase activity(CK) 
  
ΔA/min = ((Final A - Initial A) ÷ (Final Reading Time – Initial Reading time (mins)) 
 
CK (U/l) = (ΔA/min × TV × 1000) ÷ (6.22 × SV) 
CK (U/l) = (ΔA/min × 0.21 × 1000) ÷ (6.22 × 0.01)  
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Figure 2.3. Linear Relationship of a single samples absorbance (y axis) per minute at 340 nm over 34 minutes 
There is good correlation observed (r = 0.99) readings taken at 2-13 minutes (early) and 25 to 36 minutes (late) 
suggesting readings taken at an early time point are a good. 
 
2.2.5.2.   Estimation of protein concentration 
Bicinchoninic Acid™ (BCA) is used to determine the protein concentration in the cell lysates. 
Briefly, the assay detects Cu+, which is formed when Cu2+ is reduced by protein in an alkaline 
environment (Smith et al., 1985). The purple-coloured reaction product is formed by the 
chelation of two molecules of BCA with one Cu+. This water-soluble complex exhibits a 
strong absorbance between 540 and 590 nm that increases linearly with increasing protein 
concentrations. Protein concentrations were determined with reference to Bovine Serum 
Albumin (BSA) standards of known concentration that were assayed alongside the cell 
lysates. 
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2.2.7. Immunocytochemical analysis 
Cell monolayers were washed in PBS, fixed in 3.7% formaldehyde, and incubated at room 
temperature for 10 minutes. The fixative was aspirated and the wells washed 3 times for 3 
mins with PBS to remove excess paraformaldehyde prior to storage at 4°C for up to one 
week. Cells were washed briefly three times with PBS before being permeabilised with 0.1% 
Triton X-100 for 10 minutes at room temperature. Following Triton removal, cells were 
washed with PBS before staining with Texas Red-X Phalloidin at a final dilution of 1:1000. 
AntiMyosin Heavy Chain (MyHC) Alexa Fluor_488 was added at 4 µg/ml and for nuclear 
staining, 4', 6-diamidino-2-phenylindole (DAPI) was added at a final dilution of 1:5000. After 
a 30-min incubation, the treated cells were photographed using a Leica DMI 6000B imaging 
system. 
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Chapter 3 
Effect of inflammatory cytokines on old C2 and young C2C12 
myoblast muscle cells in vitro 
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3.1. Introduction 
Many chronic diseases and aging are associated with elevated systemic inflammation. 
Inflammatory cytokines, such as (TNF-α) and interleukin-6 (IL-6) have a negative impact on 
whole body function (Sprague & Khalil, 2009; Holecek, 2012), including inducing a 
reduction in muscle mass which is associated with a poor prognosis. Understanding the 
mechanisms underpinning inflammation-induced muscle wasting in chronic diseases such 
as muscular dystrophy, cancer, AIDS, chronic infections, and inflammatory myopathies, 
aging may ultimately provide routes for therapeutic interventions (Costamagna et al., 
2015a). Ways in which cytokines can affect muscle-wasting is via their impact on myoblasts 
survival and proliferation  (Yin et al., 2013). 
By contrast, several polypeptide growth factors, including (IGF-I) have been implicated as 
stimulators of myogenic survival, proliferation and differentiation (Velloso, 2008; Yin et al., 
2013). Indeed, in aged muscle, the reduction in protein synthesis that is evident, is 
associated with reduced IGF-I availability (Barbieri et al., 2003). In association with altered 
systemic environments, it is also possible that changes within the muscle itself may 
attenuate the responses to growth factor and cytokines with aging. 
The objectives of this research were to identify differences in the response to TNF-α, IL-6 
and IGF-I between the C2 and C2C12 myoblasts. It was hypothesised that responses to IL-6 
and TNF-α would be exacerbated, whereas those to IGF-I would be blunted in C2 vs. C2C12 
cells. The overarching aim of such research is to reduce muscle wasting with age. 
 
3.2. Methods 
The methods for myoblast treatment are detailed in the general methods chapter. Briefly, 
C2 and C2C12 murine skeletal myoblasts were exposed to DM, TNF-α (2.5 ng/ml or 10 
ng/ml), IGF-I (50 ng/ml or 100 ng/ml) and IL-6 (2.5 ng/ml or 10 ng/ml) for 48 and 72hrs. The 
morphological alterations in differentiation were confirmed using biochemical analyses. 
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3.3. Statistics 
All experiments were repeated three times in duplicate, unless otherwise stated, and were 
analysed, using GraphPad Prism software version 5.0 (La Jolla, CA, USA). One-way ANOVA 
was used to compare the effects of all the experimental conditions followed by Bonferroni 
post hoc analysis. Results were presented as mean ± standard deviation (SD). The 
significance was accepted as P ≤ 0.05. 
  
28 
3.2. Results 
3.2.1. Morphological differences in differentiation of young C2C12 compared with old 
C2 cells. 
Both C2 and C2C12 cells showed evidence of fusion following 48 hours incubation under 
control conditions (Figure.3.1). Following 72 hours, however, the myotubes evident in the 
C2C12 cells are more extensive and abundant than those seen in the C2 cells, suggesting 
the C2C12 cells have greater myogenic potential than C2 cells. 
 
Figure 3.1. Young C2C12 myoblasts cells showed more myotube formation compared to old C2 myoblasts cells. 
Old C2 do not differentiate as capably compared with young C2C12, which showed fully myoblasts fusion and 
differentiated myotube formation by 72hrs. Representative images of old C2 and young C2C12 mouse myoblasts 
cultured in differentiation medium (DM) for 48 and 72hrs. Arrows indicated the myotube formation in the old and 
young myoblasts.  Images are representative of 3 experiments performed in duplicate. (10× magnification). 
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3.2.2. Impact of TNF-α on mouse skeletal muscle cells during differentiation 
Experiments assessed dose responsive effects of 2.5 ng/ml or 10 ng/ml TNF-α on C2 and 
C2C12 myoblasts survival and differentiation at 48 and 72hrs. Photomicrographs illustrate 
a more potent impact of higher vs. lower dose TNF-α on the induction of cell death and 
inhibition of differentiation. This appears to be exacerbated in C2 vs. C2C12 myoblasts 
(Figure.3.2). Having determined that TNF-α is capable of reducing differentiation, most 
particularly in C2 vs. C2C12 cells, we next wished to determine the impact of IGF-I on 
cellular behaviour. 
 
 
Figure 3.2. Old C2 myoblasts cells induced more cell death compared to old C2C12 myoblasts cells. 
Images showed the lack of myotube formation and numerals of dead cells in C2 cells while C2C12 remained to 
differentiate with a few cell death. TNF-α inhibited myogenic differentiation in old C2 cells. Representative images of 
C2 and C2C12 myoblasts in the presence of TNF-α (2.5 ng/ml and 10 ng/ml) at 48 and 72 hrs. Arrows indicated the dead 
cells in young and old myoblasts. Images are representative of 3 experiments performed in duplicate. (10× 
magnification). 
 
 
 
 
 
 
 
 
 
 
30 
3.2.3. Impact of IGF-I on mouse skeletal muscle during differentiation. 
The impact of IGF-I (50 ng/ml and 100 ng/ml) on mouse skeletal myoblasts was investigated. 
In presence of IGF-I both myoblasts lines increased differentiation, however, this was greater 
in C2C12 vs. C2 cells, particularly at the higher dose (Figure.3.3). Having determined that C2 
and C2C12 cells behave differentially under basal conditions and that their ability to survive 
and differentiate is diminished in the presence of both TNF-α and stimulated by IGF-I, we next 
wished to investigate the impact of IL-6 on myoblasts differentiation. 
 
Figure 3.3. Young C2C12 myoblasts IGF-I induced more myotube formation compared to old C2 myoblasts. 
C2C12 cells treated with high IGF-I dose induced number of myotube formation and more myoblast fusion compared to 
C2 cells, specifically at 72hss. IGF-I induced myogenic differentiation in young C2C12 cells. Representative images of C2 
and C2C12 myoblasts in the presence of IGF-I (50 ng/ml and 100 ng/ml) at 48 and 72 hrs. Arrows indicated the myotube 
formation in the old and young myoblasts. Images are representative of 3 experiments performed in duplicate. (10× 
magnification). 
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3.2.4. Impact of IL-6 on mouse skeletal muscle cells.  
 
Cells were treated with IL-6 (2.5 and 10 ng/ml) for 48 or 72 hrs. IL-6 induced alteration on 
young (C2C12) and old (C2) myoblast cell morphology during differentiation. Morphological 
changes induced by IL6 were minimal at both times and in both cell lines (Figure. 3.4) 
 
Figure 3.4. Old C2 myoblasts cells induced more cell death and less myotube formation compared to young C2C12  
myoblasts cells.  
C2C12 cells remained to differentiate (myotube formation) with small number of cell death particular with high dose. 
IL-6 were inhibited myogenic differentiation in old C2 cells. Representative images of C2 and C2C12 myoblasts in the 
presence of IL-6 (2.5 ng/ml and 10 ng/ml) at 48 and 72 hrs. Arrows indicated the dead cells in the old and young 
myoblasts. Images are representative of 3 experiments performed in duplicate. (10× magnification). 
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3.4.5 Biochemical differentiation of young and old murine myoblasts  
Having determined that under control conditions, C2 cells appear to form smaller 
myotubes than C2C12 cells over a 72 hour period, are more prone to the negative impact 
of cytokines and resistant to the beneficial effects of IGF-I, we wished to confirm these 
findings at a biochemical level. Myoblasts were cultured as above and protein 
concentration and creatine kinase activity were assessed.  
C2C12 cells displayed higher protein concentrations compared to C2 cells under all culture 
conditions (Figure.3.5). TNF-α elicited a reduction in protein concentration in C2 cells, 
which was not apparent in C2C12 cells. Surprisingly, IGF-I also caused a reduction in protein 
levels in C2 cells and at higher doses in C2C12 cells. Finally, IL-6, independent of dose, 
caused a reduction in protein levels in both cell lines. 
 
Figure 3.5. Protein concentration of old C2 vs. young C2C12 mouse myoblasts in the presence and absence of TNF-α, 
IL-6 and IGF-I. 
In all condition, there was significant increased in total protein in young C2C12 cells vs. old C2 cells, in presence of TNF-
α, IGF-I and IL-6. Data is taken from 3 experiments in duplicate. Graph depicts means ± SD. ***P ≤ 0.001. 
 
 
 
 
35 
We next compared creatine kinase activity, a marker of biochemical differentiation, under 
the culture conditions described above and in both cell lines after 48hrs. C2 cells showed 
lower biochemical differentiation compared to C2C12 cells under all conditions. TNF-α 
induced a dose-dependent reduction in creatine kinase activity in both cell lines, but this 
was more pronounced in the C2 vs. the C2C12 cells. As anticipated, IGF-I elicited a dose-
responsive increase in the C2C12 cells.  By contrast, it was without beneficial effect in the 
C2 cells and indeed apparently suppressed CK activity in these cells, when compared with 
DM controls. Finally, IL-6 had little impact in both cell lines, compared with their own DM 
control. 
 
Figure 3.6. Creatine kinase (CK) activity of old C2 vs. young C2C12 mouse myoblasts in the presence and absence of 
TNF-α, IL-6 and IGF-I. 
Young C2C12 cells have higher CK activity than old C2 cells suggesting more differentiation. Data are taken from 3 
experiments, in duplicate. Graph depicts means ± SD. ***P ≤ 0.001. 
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3.3. Discussion 
Within an aging population, a key question yet to be addressed is whether younger and 
older myoblasts behave differently to encounters with hypertrophic vs. atrophic agents. 
The models developed within this chapter provide a novel system with which to begin to 
address such questions. The main morphological and biochemical observation revealed by 
these studies is a better differentiation potential in the model of younger (C2C12) vs. older 
C2) myoblasts. When examining the impact of cytokines on myoblasts behaviour, it is 
immediately apparent that the C2 cells are more susceptible to the inhibitory effects of the 
higher dose TNF-α on differentiation, compared with the C2C12 cells. This effect is not 
evident with IL6 treatment, which at the doses investigated was with little impact on either 
cell line. Finally, while the C2C12 cells responded positively to IGF-I administration, with an 
increase in differentiation, this was not the case in the C2 cells and indeed these seemed 
to be negatively influenced by this growth factor at the doses tested. Overall, these data 
suggest, using a model of older and younger myoblasts, that younger cells respond as 
anticipated to both hypertrophic and atrophic agents. In accordance with expectations, the 
older cells are more responsive to the atrophic impact of TNF-α, but in contrast to 
hypotheses, IGF-I inhibited rather than stimulated myoblasts differentiation. 
In vivo human studies suggest that a chronic, yet low level increase in systemic IL-6 may be 
responsible for the age-related decrease in muscle mass (Visser et al., 2002; Barbieri et al., 
2003; Maggio et al., 2006; Woods et al., 2012). C2C12 cells do not support this observation.  
Although there is less fusion in the C2 vs. C2C12 cells under basal conditions, neither line 
displays an atrophic response to IL-6 administration. Therefore, the loss of muscle mass 
with age, may not be attributable to an increased systemic concentration of or sensitivity 
to IL-6 in old myoblasts.   
Several studies of muscle loss with age and chronic disease suggest that TNF-α is a potent 
mediator of muscle wasting. Early in vivo rodent (Llovera et al., 1993) and in vitro cell 
models (Stewart et al., 2004) already supported this hypothesis. However, to date none 
have compared potentially exacerbated responses as a result of age. In the present study, 
we confirmed earlier observations of the detrimental impact of TNF-α on muscle cell 
differentiation. Here, we extend these findings to reveal that the differentiation of older 
C2 cells is impaired more extensively compared with the younger cell model. These data  
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complement studies by (Jejurikar et al., 2006), who reported that older myoblasts in rodent 
models in vivo are more prone to the apoptotic impact of TNF-α vs. younger cells. 
Finally, we also compared the impact of IGF-I on myoblasts behaviour. There are extensive 
data in the literature reporting the important pro-hypertrophic role of IGF-I in cells and in 
rodents e.g. ( Stewart & Rotwein, 1996). Furthermore, there are also human association 
studies to suggest a role for IGF-I in hypertrophy in younger vs. older adults (Sharples et al., 
2015). Here, we report a divergence from these reported findings. In contrast to 
expectations, the C2C12 cells responded positively to the addition of exogenous IGF-I, 
however, the C2 cells appeared to atrophy. Previously we have reported that in the 
presence of low dose TNF-α, the co-incubation with IGF-I elicits a potent atrophic, rather 
than a hypertrophic response (Saini et al., 2009). It is possible, although unlikely, that under 
the present culture conditions, exogenous IGF-I interacts with endogenously produced 
TNF-α (Greiwe et al., 2001) by the older cells and that the combined impact is an induction 
of atrophy. It is important to note that this is a hypothesis to be tested, for which we have 
no current evidence. 
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3.4. Conclusion 
In this chapter, we report the comparison of parental and daughter cells under basal and 
stimulated conditions to ascertain the capability of developing a commercially available 
muscle cell model of age- and disease-related wasting. We establish that the older C2 cells 
are less able to hypertrophy and, as hypothesised, that the induction of atrophy with 
exogenous TNF-α is greater vs. C2C12 cells.  In contrast to expectations, IL-6 had little 
impact on either cell line under the conditions of culture, whereas IGF-I elicited a 
hypertrophic effect in younger and an atrophic effect in older cells. This does indeed 
provide a useful model for further exploration of the ageing muscle cell process. 
Critically, however, these studies have been undertaken in murine myoblasts with C2 cells 
being designated as older and C2C12 as younger. They are not of human origin and not 
from old vs. young humans. Therefore, in the next chapter we assess the response of old 
and young primary human skeletal muscle cell. 
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Chapter 4 
Effects of inflammatory cytokines on the differentiation of young 
and old human myoblasts in vitro 
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4.1.1. Introduction  
Age-related muscle wasting (sarcopenia) is a significant contributor to the loss of 
physiological and functional capacity in old age (Narici & Maffulli, 2010; Seene & Kaasik, 
2012; Kalyani et al., 2014) and has been strongly linked with morbidity and mortality  
(Kalyani et al., 2014; Bonaldo & Sandri, 2013; Passey et al., 2016).  The loss of muscle mass 
occurs at a rate of 1-2% per year after the age of 50 years in humans ( Kalyani et al., 2014) 
and contributes to the majority of the age-related loss of muscle strength and therefore 
functional ability and metabolic performance of the older person (Bogdanis, 2012). More 
than 50% of the population older than 80 years suffer from sarcopenia, a condition 
recognised as a geriatric syndrome and a serious clinical disorder (Cruz-Jentoft et al., 2010; 
Kalyani et al., 2014; S. Ali & Garcia, 2014). 
While some protein mobilisation from muscle protein is beneficial in acute trauma and 
disease, slight but persistent mobilisation of muscle protein in chronic conditions may 
result over time in large protein deficits and muscle atrophy that can have significant 
implications for the patient, including impaired respiration, mobility and efficacy of 
potential treatment(Stewart et al., 2004). Moreover, the atrophied muscle may be more 
susceptible to injury during exercise and even during daily life activities ( English & Paddon-
Jones, 2010; Bogdanis, 2012). To repair such damage, satellite cells are required (Yin et al., 
2013). 
Skeletal muscle has a notable ability to repair damage (Juhas & Bursac, 2013; Yin et al., 
2013). As skeletal muscle stem cells, satellite cells play an indispensable role in this process 
(Yin et al., 2013) . The self-renewing proliferation of satellite cells not only maintains the 
stem cell population but also provides numerous myogenic cells, which proliferate, 
differentiate, fuse, and lead to repair of damaged fibres or even new myofibre formation 
and reconstitution of a functional contractile apparatus (Yin et al., 2013). 
The ability of these cells to respond to growth and differentiation signals may be dependent 
on the local growth factor/ cytokine environment (Yablonka-Reuveni et al., 1999). Indeed, 
cytokines play a crucial role in muscle regeneration by either stimulating or inhibiting 
proliferation or differentiation of myoblasts (Karalaki et al., 2009). Prolonged elevations of 
proinflammatory cytokines (e.g. TNF-α) and decreased growth factors, such as IGF-I, are 
associated with muscle wasting during aging and in several cachectic diseases e.g. AIDS,  
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rheumatoid arthritis and cancer (Saini et al., 2010; Suzuki et al., 2013). In line with this, in 
rodent models, TNF-α administration can induce a cachetic state (Stewart et al., 2004) 
while in murine C2 and C2C12 skeletal muscle cell lines, TNF-α can inhibit myoblasts 
differentiation and lead to cell death (Stewart et al., 2004). In the context of the present 
work it is important to note that circulating and local levels in skeletal muscle of TNF-α are 
increased in aging (Pedersen et al., 2003).  
It is not surprising that recent research has focused on the role of the interaction of growth 
factors and cytokines in the age-related muscle wasting. However, the majority of such in 
vitro studies have been carried out using immortalised rat and mouse muscle cell lines. 
While these studies have confirmed the importance of cytokines and IGF-I for myoblasts 
survival, differentiation and death, no studies have as yet investigated this in primary 
human myoblasts. 
Therefore, the aim of the study in this chapter is to assess the impact of IL-6 and TNF-α on 
human skeletal muscle myoblasts survival, differentiation and death. It is hypothesised that 
TNF-α and, potentially IL-6, will cause impaired proliferation and differentiation and 
increased apoptosis that will be rescued using anabolic stimuli (IGF-I). To test these 
hypotheses, we compared (1) differentiation (protein, creatine kinase and myotube 
formation) of myoblasts obtained from young and old people and (2) the impact of 
cytokines with or without concomitant IGF-I supplementation. 
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4.1.2.  Methods and materials 
4.1.2.1. Cell culture  
Young and old human skeletal myoblasts donated by the Butler-Browne laboratory (Bortoli 
et al., 2003) were grown in T75 flasks in a humidified 5% CO2 atmosphere at 37ºC in growth 
medium (GM), until 90-100 % confluence was reached. Cells were incubated in presence 
and absence of TNF-α (10 ng/ml or 20 ng/ml), IL-6 (2.5 ng/ml or 20 ng/ml) and IGF-I (50 
ng/ml or 100 ng/ml). For detailed methods of culture, cell isolation, histology and analyses, 
please see chapter 2.  
4.1.3. Statistical analysis 
Statistical evaluation of data was performed using Student’s t-tests. Results are presented 
as mean ± standard deviation (SD). Differences are considered significant at P≤ 0.05. 
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4.2 Results  
4.2.1. Morphological differentiation of young and old human myoblasts 
Following transfer to differentiation medium, both young and old myoblasts were able to 
form large myotubes by 48hrs (Figure.4.1). Exogenous addition of TNF-α inhibited 
differentiation of both young and old myoblasts irrespective of dose (Figure.4.1). In the 
presence of the low dose of IGF-I, myoblasts fusion appeared to be impaired in both young 
and old human cells. At the higher dose of IGF-I there was little impact on fusion in young 
cells compared to baseline, but a small facilitation of fusion in old cells (Figure.4.2). Finally, 
addition of IL-6 to the human myoblasts appeared to be without significant impact on 
fusion potential in both young and old myoblasts, irrespective of dose (Figure.4.3). 
 
Figure 0.1.TNF-α block differentiation and induced less myotube formation in both young and old myoblasts cells. 
Morphological images of young and old human myoblasts were induced to differentiate in the absence or presence of 
TNF-α (10 ng/ml and 20 ng/ml) at 48 hrs. Representative images show the lack of myotube formation and presence of 
numeral of cell dead cells in old and young cells, cell death was marked at the high dose of TNF-α. The white arrows 
showed dead cells. Images are representative of 3 experiments performed in duplicate. (10× magnification). 
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Figure 0.2. IGF-I induced myoblasts fusion and myotube formation in young and old myoblasts cells.  
Representative images of young and old human myoblasts in the absence or presence of IGF-I (30 ng/ml and 100 ng/ml) 
at 48 hrs. Images were showed differentiation and fusion of myoblast induced by IGF-I. Also Images were showed fully 
differentiated myotube in presence of numeral of cell dead in old and young myoblasts cells , especially with high IGF-
I dose. The white arrows show the myotube formation in young and old myoblasts. Images are representative of 3 
experiments performed in duplicate. (10× magnification). 
 
 
 
Figure 0.3. IL-6 induced myotube formation in young and old human myoblasts cells with little number of cell dead. 
Representative images of young and old human myoblasts in the absence or presence of IL‐6 (10 ng/ml and 20 ng/ml) 
at 48 hrs. Images showed the myotube formation and myoblasts fusion in presence of numeral of cell dead in old and 
young myoblasts cells. IL-6 induced differentiation and fusion in old and young myoblast cells. The white arrows show 
myotube formation and dead cells. Images are representative of 3 experiments performed in duplicate. (10× 
magnification).  
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4.2. Biochemical differentiation of young and old human myoblasts 
Following 48hrs of incubation in differentiation medium, protein levels were significantly 
higher in old vs. young myoblasts, irrespective of culture conditions (Figure.4.4). The 
creatine kinase assay provided evidence to suggest that old myoblasts are better at 
biochemical differentiation compared with young human myoblasts, regardless of 
treatment conditions. Furthermore, TNF-α induced a reduction in fusion in both old and 
young human myoblasts, irrespective of concentration (Figure.4.5), supporting the 
morphological findings. Again, in line with the morphological data, creatine kinase activity 
was reduced in the presence of the low dose of IGF-I in both young and old cells. The higher 
dose of IGF-I improved fusion in old and had little impact on fusion in young human 
myoblasts (Figure.4.5). In contrast to morphological data suggesting no impact on 
myoblasts fusion, the biochemical data indicate a suppression of differentiation in response 
to IL-6, most marked in the older human cells (Figure.4.5). 
 
Figure 4.4 Creatine kinase (CK) activity of old vs. young human myoblasts at 48hrs in the absence or presence of TNF-
α, IGF-I and IL-6. 
Basally (DM) and IGF-I, the old cells have higher CK activity than young cells. Old cells and young cells have reduced CK 
activity in TNF-α  and IL-6 condition. Data are taken from two experiments. Mean value ± SE (*P ≤ 0.05, **P ≤ 0.01, ***P 
≤ 0.001). Data are taken from two experiments. Mean value ± SE (*P ≤0.05, **P < 0.01, *** P < 0.001) statistically 
significant. 
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Figure 0.4. Total Protein concentration of old  vs. young human myoblasts cells at 48hrs . 
 In all conditions, there was significant increase in total protein in old cells vs. young cells in presence of TNF-α, IGF-I and 
IL-6. Total Protein concentrations in old and old human myoblasts at 48hrs in the absence or presence of TNF-α, IGF-I 
and IL-6. Data are taken from two experiments, in duplicate. (*P <0.05, **P < 0.01, ***P < 0.001) statistically significant. 
 
 
 
4.2.3. Immunocytochemical markers of differentiation in young and old human 
myoblasts 
The morphological and biochemical analyses revealed that TNF-α impaired fusion 
myoblasts. The derived data for IGF-I and IL-6 revealed some unexpected results, which 
warranted further investigation. To facilitate this process, cells were stained for actin and 
myosin (Figure.4.6). Easier visualisation of myotubes consolidated the prior findings, 
confirming reduced fusion in the presence of the low dose IGF-I in both young and old cells 
and improved fusion in old cells only at the higher dose (Figure.4.6). In line with the 
biochemical data, the immunocytochemical studies suggest that IL-6 suppressed 
differentiation (Figure.4.6). 
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Figure 0.5. Immunofluorescent staining of young and old human myoblasts cells in the absence or presence of IGF-I 
and IL-6 at 48hrs.  
Figure ( And B) young and old myoblasts cells were cultured in differentiation medium in presence or absence of A) I 
GF-I or B) IL-6  for 48 hrs to induce myotube formation. Cells were fixed and stained with anti MHC (green), Phalloidin 
(red) and DAPI (blue). Bright field images of differentiated old and young myoblast cultured in differentiation medium 
(DM) in presence and absence of IGF-I and IL-6. Merged images showed old and young myoblasts stained with anti MHC 
and Phalloidin to visualize myotubes. In addition, nuclei were visualized by DAPI staining. In A) it can be seen that high 
IGF-I dose improved the old myoblast fusion. Scale bar =25 µm. Images were captured with a Leica DMI6000B 
microscope. 
 
 
 
 
A 
B 
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4.3. Discussion 
Following the assessment of changes in murine models of age and inflammation, this 
chapter was devoted to extending murine models into old and young human myoblasts 
cultures. It was observed that old human myoblasts are capable of improved fusion 
compared with young human myoblasts. While TNF-α induced a reduction in fusion in both 
old and young human myoblasts, the response to IGF-I differed, in that the higher dose IGF-
I improved fusion in old but had little impact on fusion in young human myoblasts. IL-6 
suppressed differentiation, which was most marked in the older human cells. 
In contrast to expectations and to extensive literature indicating age-related muscle 
wasting e.g.(Degens, 2007), we provide evidence to suggest that old muscle cells are in fact 
capable of efficient fusion. In contrast to the hypothesis that older muscles are less able to 
regenerate following injury compared with young muscle (Conboy et al., 2005; Carlson & 
Faulkner, 1989), the Harridge’s group (Alsharidah et al., 2013) provide convincing data to 
suggest that under basal conditions, mixed muscle-derived cell populations isolated from 
older or younger donors are indistinguishable in terms of myogenic potential. These 
apparently conflicting findings provide important insights into the role of the local. 
Systemic environment on myoblast behaviour. Our derived data extend the findings of 
Alsharidah et al. (2013), whereby a pure population of human myoblasts suggests even an 
improved capability of old muscle cell fusion.  
To assess whether young and old myoblasts respond differently to the local environment, 
cells were exposed to equivalent culture conditions in the presence of relevant anabolic 
and catabolic agents. In line with expectations, TNF-α reduced myoblasts fusion (Stewart 
et al., 2004), however, the degree of impairment was similar in both young and older 
myoblasts. The inhibition of fusion in the presence of IL-6 was greater in older than younger 
cells, perhaps underlying the age-related muscle wasting phenotype (Visser et al., 2002). 
These findings do indicate that cytokines impact negatively on human-derived muscle cells 
and that cell age impacts on behaviour, although differing mechanisms of adaptation 
warrant investigation. 
Wishing to determine the impact of a hypertrophic agent on human myoblasts adaptation, 
we investigated the response of the cells to IGF-I (e.g.( Stewart & Rotwein, 1996). 
Surprisingly, the lower dose of IGF-I resulted in a reduction, not an increase, in myoblasts  
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fusion in young and old myoblasts. By contrast, in old myoblasts, only, there was a 
hypertrophic response to the higher dose IGF-I. It has been reported that IGF-I acts to 
promote survival and proliferation as well as differentiation of myoblasts. One could 
therefore speculate, given the current data, that in younger cells IGF-I acts to facilitate 
survival as a dominant output, but in older cells, fusion is the preferential response. This is 
supported by data of Edstrom and Ulfhake suggesting the sarcopenia is not due to a lack of 
regenerative drive in old muscle (Edström & Ulfhake, 2005).  
4.4. Conclusion 
This chapter provides evidence of the development of a relevant human myoblasts model 
to study both fusion potential with age and the response of myoblasts to environmental 
stimuli. In addition to differences in basal fusion capability, where older myoblasts are as 
efficient as, or better than, younger myoblasts at forming myotubes, both young and old 
appear to respond differently to anabolic and catabolic stimuli. 
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Chapter 5 
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5.1. General Discussion 
At the outset of this programme of research, it was hypothesised that murine and human 
myoblasts could be utilised interchangeably as models of muscle ageing and atrophy. 
Objectives were to investigate basal fusion potential of older and younger myoblasts and 
to examine the subsequent impact of growth factor/cytokine administration on myoblast 
differentiation. The aim was to provide a viable and relevant muscle cell model that can be 
used to reliably predict or screen the response to modulators of muscle mass. Table.5.1 
summarises the main findings of the studies. 
Table 0.1. Summarises the main findings of the studies 
Summary of the differentiation responses of young and old human and murine myoblasts. In the control row, arrows 
indicate fusion differences between young and old cells and in the other rows, arrows indicate the response to the 
trigger administered, in the absence of an arrow, there was no change from baseline. 
 
  Mouse Model Human Model 
C2C12(Young) C2(Old) Young Old 
Control         
IGF-I low 
 
      
IGF-I high         
TNF-α         
IL-6         
 
In the murine model, and in line with expectations, the higher dose IGF-I resulted in 
improved fusion in younger, but reduced fusion in older, myoblasts. By contrast and 
unexpectedly, in human myoblasts the opposite observation was made, where the higher 
dose of IGF-I resulted in reduced fusion in younger but increased fusion in older myoblasts. 
The improved fusion in both models was associated with enhanced fusion potential at the 
baseline, which should therefore be considered when choosing models of study. It is 
currently not known what drives altered basal fusion capability and the subsequent 
enhanced response to IGF-I. Therefore, the two models together provide an opportunity to 
further investigate this finding.  
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When assessing the impact of catabolic cytokines on myoblasts fusion, both models were 
consistent in greater negative responses elicited by older vs. younger myoblasts, despite 
differences in detail e.g. older murine myoblasts are more responsive to TNF-α and older 
human myoblasts to IL-6 administration. The impaired differentiation in response to the 
cytokines may underlie the muscle wasting evident in older age. 
In progressing these models further, several questions arise relating to both growth factor 
and cytokine responses, however the most exciting questions which immediately arise are 
related to basal and IGF-I responses, as follows: 
1. What defines the basal difference in fusion capacity within the two models? 
2. Why do the two models differ in their age-related response to IGF-I? 
To address these questions, molecular and intracellular signalling technologies need to be 
applied. If fundamental mechanisms can be determined and manipulated, they provide 
relevant information for pharmacological interventions in muscle wasting disorders. 
5.2. Limitations 
Interactions between growth factors and cytokines, which are known to play an important 
role in muscle behaviour, have not been investigated. It is also noted that in any organism, 
there are significantly more factors that impact in concert than those which we have 
chosen to study here in isolation. However, as an advantage, the approach utilised here 
can define cleanly the role of an isolated stimulus on, in this case, myoblasts behaviour that 
can be used as a foundation for further study. 
5.3. Conclusion 
The concluding observation of these studies is that the impact of aging on fusion capability 
differs between murine and human myoblasts. Part of the differential response to stimuli 
in these models may be related to the basal differences in fusion capacity. Therefore, care 
should be exerted when selecting the model of choice as the two cannot be used 
interchangeably. They do, however, potentially provide useful stand-alone models to 
investigate the mechanisms of action of a wide variety of stimuli that have an impact on 
muscle mass.
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5.4. Future directions 
On the basis of the findings of this research, there arise a number of options for future 
research including: 
 Molecular analysis to ascertain difference between key genes involved in the 
proliferation and differentiation, including IGF-I, myogenic differentiation factor 
(MyoD, myogenin, Id3) and TNF-α in normal differentiation conditions. 
 This thesis has shown that differentiation potential and the differentiation time 
course were different between cells from the young and old at different time 
courses. We would have next examined the different groups age at different time 
course.  
 The work presented in this thesis has shown the impact of TNF-α, IL-6 and IGF-I on 
young and old skeletal myoblasts cells, which have effects on myogenic behaviour 
in a dose-dependent manner. The next step would be to study the signalling 
pathways involved to determine the interaction between the TNF-α and IGF-I or IL-
6 and IGF-I, which affect skeletal muscle. 
 Another potential consideration for future work would be to alter the method of 
protein analysis for western blot analysis; blots could be stripped and probed using 
a control such as actin or tubulin. These proteins are often used as a control because 
their levels are rarely changed by treatment and provide a method to verify that the 
same amount of sample protein has been loaded in each gel lane and transferred 
to the membrane. 
 Obtaining muscle biopsies from elderly and young subjects would allow assessment 
of cellular and molecular differences. 
 To further understand the mechanism behind the differences in differentiation and 
TNF-α induced apoptosis between young and old cell, an investigation of 
cytoplasmic and nuclear protein that may be involved could be undertaken. 
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6.1. Web sites 
http://www.bdcompany.com/ 
www.sigmaaldrich.com 
6.2  Appendix 1 
 
Figure 0.1. Total fusion index of old and young myoblast cells. 
Fusion index was measured in myotube differentiated in presence and absent IGF-I and IL-6 for 48hrs. Total fusion index 
analysis representing the number of nuclei in differentiated myotubes divided by total number of nuclei present in the 
observed field, with a myotube defined by at least 2 myonuclei. Nuclei were counted from random fields of each line 
at 5 in DM, IGF-I and IL-6 in a varying doses (determine by immunofluorescence staining) P value was determined with 
a t-test. Data presented as average ±SD. *** p≤0.001. 
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6.3. Appendix 2 
 
Figure 0.2. The percentage of myotubes of young and old myoblasts cells. 
The percentage of myotubes in the cell cultures after administration of 30 ng/ml or 100 ng/ml IGF-I and 10 ng/ml or 20 
ng/ml IL6. Effect of IL-6 and IGF-I stimulation on myotube formation at 48hrs of differentiation. The percentage of 
myotubes was higher with higher doses at 72hrs in old cells vs. young cells. P value was determined with a t test. Data 
presented as average ±SD. *** p≤0.001. 
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